Akebia Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 78.77. In total, the insiders bought 11 166 738 and sold 781 354 AKBA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
78.77
Buy 11 166 738 Shares
Sell 781 354 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 28, 2024 Stock Option (Right to buy) Buy Ostrowski Erik 500 000
Jun 28, 2024 Common Stock Buy Ostrowski Erik 350 000
Jun 24, 2024 Buy Ostrowski Erik 0
Jun 06, 2024 Common Stock Buy Wolf Myles 30 000
Jun 06, 2024 Stock Option (Right to buy) Buy Wolf Myles 45 000
Jun 06, 2024 Common Stock Buy Smith Cynthia 30 000
Jun 06, 2024 Stock Option (Right to buy) Buy Smith Cynthia 45 000
Jun 06, 2024 Common Stock Buy Rogers Michael W 30 000
Jun 06, 2024 Stock Option (Right to buy) Buy Rogers Michael W 45 000
Jun 06, 2024 Common Stock Buy Gilman Steven C 30 000
Jun 06, 2024 Stock Option (Right to buy) Buy Gilman Steven C 45 000
Jun 06, 2024 Common Stock Buy Frieson Ron 30 000
Jun 06, 2024 Stock Option (Right to buy) Buy Frieson Ron 45 000
Jun 06, 2024 Common Stock Buy Zumwalt Leanne M 30 000
Jun 06, 2024 Stock Option (Right to buy) Buy Zumwalt Leanne M 45 000
Jun 06, 2024 Common Stock Buy Adams Adrian 30 000
Jun 06, 2024 Stock Option (Right to buy) Buy Adams Adrian 45 000
May 13, 2024 Common Stock Sell Hadas Nicole R. 12 016
May 13, 2024 Common Stock Sell Dahan Michel 34 840
Feb 29, 2024 Common Stock Sell Dahan Michel 8 661
Feb 29, 2024 Common Stock Sell Hadas Nicole R. 5 974
Feb 29, 2024 Common Stock Sell Butler John P. 46 570
Feb 29, 2024 Common Stock Sell Burke Steven Keith 7 169
Feb 27, 2024 Common Stock Sell Hadas Nicole R. 7 411
Feb 27, 2024 Common Stock Sell Dahan Michel 10 744
Click to get the best stock tips daily for free!

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT